Codeine-induced hyperalgesia and allodynia: Investigating the role of glial activation

Translational Psychiatry

Volumn 4, Issue 11, 2014, Pages

  Johnson, J L ^a   Rolan, P E ^a,b   Johnson, M E ^c   Bobrovskaya, L ^c   Williams, D B ^c   Johnson, K ^d   Tuke, J ^a   Hutchinson, M R ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b ROYAL ADELAIDE HOSPITAL   (Australia)

^c UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^d Medicinova   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; CODEINE; GLIAL FIBRILLARY ACIDIC PROTEIN; IBUDILAST; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; MORPHINE; OPIATE RECEPTOR; SODIUM CHLORIDE; TOLL LIKE RECEPTOR 4; IL1RN PROTEIN, MOUSE; NARCOTIC ANALGESIC AGENT; TLR4 PROTEIN, MOUSE;

ADULT; ALLODYNIA; ANALGESIA; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; GLIA CELL; HYPERALGESIA; LIGHT DARK CYCLE; MALE; MOUSE; NERVE INJURY; NOCICEPTION; NONHUMAN; RISK BENEFIT ANALYSIS; VON FREY TEST; ANIMAL; BAGG ALBINO MOUSE; CHEMICALLY INDUCED; COMPARATIVE STUDY; DRUG EFFECTS; GLIA; INJURIES; KNOCKOUT MOUSE; METABOLISM; PAIN THRESHOLD; RANDOMIZATION; SCIATIC NERVE;

ANALGESICS, OPIOID; ANIMALS; BEHAVIOR, ANIMAL; CODEINE; HYPERALGESIA; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; MORPHINE; NEUROGLIA; PAIN THRESHOLD; RANDOM ALLOCATION; SCIATIC NERVE; TOLL-LIKE RECEPTOR 4;

EID: 84927913514     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2014.121     Document Type: Article

References (54)

1. Fishbain DA, Cole B, Lewis JE, Gao J, Rosomoff RS. Do opioids induce hyperalgesia in humans? An evidence-based structured review. Pain Med 2009; 10: 829-839.
2. MacFadyen L, Eadie D, McGowan T. Community pharmacists' experience of overthe-counter medicine misuse in Scotland. J R Soc Promot Health 2001; 121: 185.
3. Murnion BP. Combination analgesics in adults. Aust Prescr 2010; 33: 113-115.
4. Hamunen K, Laitinen-Parkkonen P, Paakkari P, Breivik H, Gordh T, Jensen NH et al. What do different databases tell about the use of opioids in seven European countries in 2002? Eur J Pain 2012; 12: 705-715.
5. Hamunen K, Paakkari P, Kalso E. Trends in opioid consumption in the Nordic countries 2002-2006. Eur J Pain 2009; 13: 954-962.
6. Fredheim OMS, Skurtveit S, Moroz A, Breivik H, Borchgrevink PC. Prescription pattern of codeine for non-malignant pain: a pharmacoepidemiological study from the Norwegian Prescription Database. Acta Anaesthesiol Scand 2009; 53: 627-633.
7. Coller J, Christrup L, Somogyi A. Role of active metabolites in the use of opioids. Eur J Clin Pharmacol 2009; 65: 121-139.
8. Eckhardt K, Li S, Ammon S, Schänzle G, Mikus G, Eichelbaum M et al. Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation. Pain 1998; 76: 27-33.
9. Holmquist G. Opioid metabolism and effects of cytochrome P450. Pain Med 2009; 10: S20-S29.
10. Vree T, Verwey-Van Wissen C. Pharmacokinetics and metabolism of codeine in humans. Biopharm Drug Dispos 1992; 13: 445-460.
11. Adams M, Lennard MS, Otton SV, Tucker GT, Woods HF. Assessment of the mouse as an experimental model for studying polymorphic oxidation of the sparteine/debrisoquine type. Biochem Pharmacol 1991; 42: 947-949.
12. Ossipov MH, Lai J, King T, Vanderah TW, Porreca F. Underlying mechanisms of pronociceptive consequences of prolonged morphine exposure. Biopolymers 2005; 80: 319-324.
13. Hutchinson MR, Bland ST, Johnson KW, Rice KC, Maier SF, Watkins LR et al. Opioid-induced glial activation: mechanisms of activation and implications for opioid analgesia, dependence, and reward. ScientificWorldJournal 2007; 7: 98-111.
14. Hutchinson MR, Coats BD, Lewis SS, Zhang Y, Sprunger DB, Rezvani N et al. Proinflammatory cytokines oppose opioid-induced acute and chronic analgesia. Brain Behav Immun 2008; 22: 1178-1189.
15. Hutchinson MR, Lewis SS, Coats BD, Rezvani N, Zhang Y, Wieseler JL et al. Possible involvement of toll-like receptor 4/myeloid differentiation factor-2 activity of opioid inactive isomers causes spinal proinflammation and related behavioral consequences. Neuroscience 2010; 167: 880-893.
16. Hutchinson MR, Northcutt AL, Hiranita T, Wang X, Lewis SS, Thomas J et al. Opioid activation of toll-like receptor 4 contributes to drug reinforcement. J Neurosci 2012; 32: 11187-11200.
17. Célèrier E, Rivat C, Jun Y, Laulin JP, Larcher A, Reynier P et al. Long-lasting hyperalgesia induced by fentanyl in rats: preventive effect of ketamine. Anesthesiology 2000; 92: 465-472.
18. Jacquet YF, Lajtha A. Morphine action at central nervous system sites in rat: analgesia or hyperalgesia depending on site and dose. Science 1973; 182: 490-492.
19. Johnson JL, Hutchinson MR, Williams DB, Rolan P. Medication-overuse headache and opioid-induced hyperalgesia: a review of mechanisms, a neuroimmune hypothesis and a novel approach to treatment. Cephalalgia 2013; 33: 52-64.
20. Hutchinson MR, Zhang Y, Shridhar M, Evans JH, Buchanan MM, Zhao TX et al. Evidence that opioids may have toll-like receptor 4 and MD-2 effects. Brain Behav Immun 2010; 24: 83-95.
21. Grace PM, Hutchinson MR, Manavis J, Somogyi AA, Rolan PE. A novel animal model of graded neuropathic pain: utility to investigate mechanisms of population heterogeneity. J Neurosci Methods 2010; 193: 47-53.
22. Bennett GJ, Xie YK. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 1988; 33: 87-107.
23. Barrot M. Tests and models of nociception and pain in rodents. Neuroscience 2012; 211: 39-50.
24. Nicotra L, Tuke J, Grace P, Rolan PE, Hutchinson MR. Sex differences in mechanical allodynia: how can it be preclinically quantified and analysed? Front Behav Neurosci 2014; 8: 40.
25. Ankier SI. New hot plate tests to quantify antinociceptive and narcotic antagonist activities. Eur J Pharmacol 1974; 27: 1-4.
26. R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing: Vienna, Austria, 2013; http://www.R-project.org/.
27. Bates D, Maechler M, Bolker B, Walker S lme4: linear mixed-effects models using Eigen and S4. R package version 1.0-5 2013; http://CRAN.R-project.org/package = lme4.
28. Hothorn T, Bretz F, Westfall P. Simultaneous inference in general parametric models. Biom J. 2008; 50: 346-363.
29. Wickham H. The split-apply-combine strategy for data analysis. J Stat Softw 2011; 40: 1-29.
30. Venables WN, Ripley BD. Modern Applied Statistics with S, 4th edn. Springer: New York, NY, USA, 2002.
31. Glenn JA, Sonceau JB, Wynder HJ, Thomas WE. Histochemical evidence for microglia-like macrophages in the rat trigeminal ganglion. J Anat 1993; 183: 475-481.
32. Aita M, Byers MR, Chavkin C, Xu M. Trigeminal injury causes kappa opioiddependent allodynic, glial and immune cell responses in mice. Mol Pain 2010; 6: 8.
33. Erickson PA, Feinstein SC, Lewis GP, Fisher SK. Glial fibrillary acidic protein and its mRNA: ultrastructural detection and determination of changes after CNS injury. J Struct Biol 1992; 108: 148-161.
34. Middeldorp J, Hol EM. GFAP in health and disease. Prog Neurobiol 2011; 93: 421-443.
35. Hanani M. Satellite glial cells in sensory ganglia: from form to function. Brain Res Brain Res Rev 2005; 48: 457-476.
36. Perry VH, Hume DA, Gordon S. Immunohistochemical localization of macrophages and microglia in the adult and developing mouse brain. Neuroscience 1985; 15: 313-326.
37. Raghavendra V, Rutkowski MD, DeLeo JA. The role of spinal neuroimmune activation in morphine tolerance/hyperalgesia in neuropathic and shamoperated rats. J Neurosci 2002; 22: 9980-9989.
38. Torre ER, Lothman E, Steward O. Glial response to neuronal activity: GFAP-mRNA and protein levels are transiently increased in the hippocampus after seizures. Brain Res 1993; 631: 256-264.
39. Hutchinson M, Lewis SS, Coats B, Skyba DA, Crysdale N, Berkelhammer DL et al. Reduction of opioid withdrawal and potentiation of acute opioid analgesia by systemic AV411 (ibudilast). Brain Behav Immun 2009; 23: 240-250.
40. Song P, Zhao ZQ. The involvement of glial cells in the development of morphine tolerance. Neurosci Res 2001; 39: 281-286.
41. Li Q. Antagonists of toll like receptor 4 maybe a new strategy to counteract opioid-induced hyperalgesia and opioid tolerance. Med Hypotheses 2012; 79: 754-756.
42. Greenhalgh AD, Galea J, Dénes A, Tyrrell PJ, Rothwell NJ. Rapid brain penetration of interleukin-1 receptor antagonist in rat cerebral ischaemia: pharmacokinetics, distribution, protection. Br J Pharmacol 2010; 160: 153-159.
43. Clark SR, McMahon CJ, Gueorguieva I, Rowland M, Scarth S, Georgiou R et al. Interleukin-1 receptor antagonist penetrates human brain at experimentally therapeutic concentrations. J Cereb Blood Flow Metab 2008; 28: 387-394.
44. Shavit Y, Wolf G, Goshen I, Livshits D, Yirmiya R. Interleukin-1 antagonizes morphine analgesia and underlies morphine tolerance. Pain 2005; 115: 50-59.
45. Rolan P, Hutchinson M, Johnson K. Ibudilast: a review of its pharmacology, efficacy and safety in respiratory and neurological disease. Expert Opin Pharmacother 2009; 10: 2897-2904.
46. Cho Y, Crichlow GV, Vermeire JJ, Leng L, Du X, Hodsdon ME et al. Allosteric inhibition of macrophage migration inhibitory factor revealed by ibudilast. Proc Natl Acad Sci USA 2010; 107: 11313-11318.
47. Gibson LCD, Hastings SF, McPhee I, Clayton RA, Darroch CE, Mackenzie A et al. The inhibitory profile of Ibudilast against the human phosphodiesterase enzyme family. Eur J Pharmacol 2006; 538: 39-42.
48. Johnson K, Matsuda K, Iwaki Y. Ibudilast for the treatment of drug addiction and other neurological conditions. Clin Invest 2014; 4: 269-279.
49. Mizuno T, Kurotani T, Komatsu Y, Kawanokuchi J, Kato H, Mitsuma N et al. Neuroprotective role of phosphodiesterase inhibitor ibudilast on neuronal cell death induced by activated microglia. Neuropharmacology 2004; 46: 404-411.
50. Lilius TO, Rauhala PV, Kambur O, Kalso EA. Modulation of morphine-induced antinociception in acute and chronic opioid treatment by ibudilast. Anesthesiology 2009; 111: 1356-1364.
51. Ledeboer A, Liu T, Shumilla JA, Mahoney JH, Vijay S, Gross MI et al. The glial modulatory drug AV411 attenuates mechanical allodynia in rat models of neuropathic pain. Neuron Glia Biol 2006; 2: 279-291.
52. Islam AK, Cooper ML, Bodnar RJ. Interactions among aging, gender, and gonadectomy effects upon morphine antinociception in rats. Physiol Behav 1993; 54: 45-53.
53. Liu L, Coller JK, Watkins LR, Somogyi AA, Hutchinson MR. Naloxone-precipitated morphine withdrawal behavior and brain IL-1Î2 expression: Comparison of different mouse strains. Brain Behav Immun 2011; 25: 1223-1232.
54. Headache Classification Committee of the International Headache Society. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia 2006; 26: 742-746.